Skip to main content

Table 5 ASAS40 and BASDAI 50 response rates at week 12 in patients with AS stratified by prior anti-TNF therapy

From: Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy

 

ASAS40

BASDAI 50

 

Response rate, n/N(%)

Unadjusted odds ratio

Pvalue

Response rate, n/N(%)

Unadjusted odds ratio

Pvalue

  

(95% CI)

  

(95% CI)

 

History of prior anti-TNF therapy

      

   Prior ETN or IFX or both

115/305 (37.7)

0.41 (0.32 to 0.54)

< 0.001

128/314 (40.8)

0.40 (0.31 to 0.53)

< 0.001

   No prior ETN/IFXa

518/873 (59.3)

  

561/890 (63.0)

  

Prior TNF antagonist(s)

      

   ETN only

25/81 (30.9)

0.93 (0.47 to 1.83)

0.083

27/81 (33.3)

0.98 (0.51 to 1.90)

0.033

   IFX only

66/150 (44.0)

1.64 (0.91 to 2.93)

 

75/156 (48.1)

1.82 (1.03 to 3.20)

 

   ETN and IFXa

24/74 (32.4)

  

26/77 (33.8)

  

Reason for discontinuation of prior TNF antagonist

      

   Loss of response

46/108 (42.6)

2.09 (1.05 to 4.14)

0.108

47/112 (42.0)

2.03 (1.03 to 4.03)

0.059

   Intolerance

20/52 (38.5)

1.76 (0.79 to 3.91)

 

25/54 (46.3)

2.42 (1.11 to 5.30)

 

   Lack of responsea

16/61 (26.2)

  

16/61 (26.2)

  
  1. aUsed as reference value. AS, ankylosing spondylitis; ASAS40, Assessment of SpondyloArthritis international Society 40% response; BASDAI 50, Bath AS Disease Activity Index 50% response; CI, confidence interval; ETA, etanercept; IFX, infliximab; TNF, tumor necrosis factor.